Patents Assigned to Voyager Therapeutics, Inc.
  • Tau binding compounds
    Patent number: 12291565
    Abstract: The present disclosure provides anti-tau antibodies and vectorization thereof (e.g., into AAV particles). Also provided are methods of using anti-tau antibodies and/or AAV particles for prevention, treatment, and/or diagnosis of neurological indications.
    Type: Grant
    Filed: June 5, 2024
    Date of Patent: May 6, 2025
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Wencheng Liu, Todd Carter, Ishan Sanjeev Shah, Christopher Joseph Murray, James Bernard McClory, Dinah Wen-Yee Sah
  • Frataxin expression constructs having engineered promoters and methods of use thereof
    Patent number: 12281321
    Abstract: The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of frataxin (FXN), whether in vitro and/or in vivo including, but not limited to, the exploitation of engineered promoters. Such compositions include delivery via administration of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Friedreich's ataxia or another neuromuscular or neurological condition resulting from a deficiency in the quantity and/or function of frataxin or associated with decreased expression or protein levels of frataxin.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 22, 2025
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Holger Patzke, Jinzhao Hou, Hongxing Wang, Yanqun Shu, Martin Goulet, Dinah Wen-Yee Sah
  • Chimeric capsids
    Patent number: 12180500
    Abstract: The present invention relates to viral vectors and methods of their production and use.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: December 31, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Robert Kotin, Jinzhao Hou, James McLaughlin
  • Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
    Patent number: 12146150
    Abstract: Described herein are compositions and methods for treating Friedreich's Ataxia (FA) using adeno-associated virus (AAV) to deliver therapeutics agents.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: November 19, 2024
    Assignees: VOYAGER THERAPEUTICS, INC., INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE STRASBOURG
    Inventors: Dinah Wen-Yee Sah, Martin Goulet, Holger Patzke, Yanqun Shu, Jinzhao Hou, Hélène Puccio
  • Methods for measuring the potency of AADC viral vectors
    Patent number: 12129476
    Abstract: The present disclosure presents improved analytical tools, systems and methods related to AADC viral vectors, including AADC potency assays for measuring and analyzing AADC expression potency (i.e. enzymatic activity) related to AADC vectors such as adeno-associated virus (AAV) AADC vectors.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 29, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Lauren M. Drouin, Patrick Starremans, Eric D. Horowitz, Carlo Ciatto, Joseph Mombeleur
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 12123002
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 22, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Treatment of amyotrophic lateral sclerosis (ALS)
    Patent number: 12116589
    Abstract: The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: October 15, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Qingmin Chen, Joan R. Coates, Holger Patzke, Jinzhao Hou
  • Modulatory polynucleotides
    Patent number: 12084659
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: September 10, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu Nonnenmacher
  • Modulatory polynucleotides
    Patent number: 12071625
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: August 27, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou
  • Engineered untranslated regions (UTR) for AAV production
    Patent number: 12060567
    Abstract: The present disclosure describes methods and systems for use in the production of recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of AAV capsid proteins, such as VP1, VP2 and VP3. In certain embodiments, the production process and system include engineered untranslated regions (UTR) which allow for the controlled expression of non-structural AAV replication proteins, such as Rep78 and Rep52.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 13, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Luis Maranga, Sylvain Cecchini, David Dismuke
  • AADC polynucleotides for the treatment of Parkinson's disease
    Patent number: 11975056
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: May 7, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Robert Kotin, Adrian Philip Kells, Bernard Ravina
  • Compositions and methods for treating Huntington's disease
    Patent number: 11951121
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 9, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • Treatment of amyotrophic lateral sclerosis (ALS)
    Patent number: 11931375
    Abstract: The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: March 19, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Holger Patzke, Qingmin Chen, Jenna Carroll Soper
  • AAV capsids with increased tropism to brain tissue
    Patent number: 11859200
    Abstract: The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: January 2, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Mathieu E. Nonnenmacher, Jinzhao Hou, Wei Wang, Matthew Child, Shaoyong Li
  • AADC polynucleotides for the treatment of Parkinson's disease
    Patent number: 11759506
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: September 19, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Maria Scheel, Bernard Ravina
  • Compositions and methods of treating Huntington's disease
    Patent number: 11752181
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 12, 2023
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Compositions and methods for the production of scAAV
    Patent number: 11697825
    Abstract: The present invention is directed to viral vectors and methods of their production and use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 11, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: James McLaughlin, Robert Kotin
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 11603542
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 14, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Qingmin Chen, Jinzhao Hou
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 11542506
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 3, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS FOR THE TREATMENT OF DISEASE
    Publication number: 20220395544
    Abstract: The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody-like pol peptides, for the prevention and/or treatment of diseases and/or disorders.
    Type: Application
    Filed: April 8, 2022
    Publication date: December 15, 2022
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Steven Paul, Donna T. Ward